Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Skin and subcutaneous tissue disorders – page 31

  • 844 clinical trials
  • 268 recruiting
  • 353 conditions
  • 25 countries

Conditions in this area

353 conditions with trials, the busiest first

Dermatitis atopic88Malignant melanoma79Systemic lupus erythematosus61Psoriasis53Hidradenitis47Psoriatic arthropathy46Systemic scleroderma39Metastatic malignant melanoma32Vitiligo23Hereditary angioedema22Chronic spontaneous urticaria19Malignant melanoma stage III17Dermatomyositis15Non-small cell lung cancer15Alopecia areata14Cutaneous lupus erythematosus14Rheumatoid arthritis14Diabetic foot13Basal cell carcinoma12Malignant melanoma stage IV12Actinic keratosis11Hepatocellular carcinoma11Neurodermatitis11Squamous cell carcinoma of skin11+329

Clinical trials in Skin and subcutaneous tissue disorders

844 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

844 clinical trials

Actinic keratosis

Not yet recruiting

Study on the Effectiveness and Safety of Metformin and Methyl Aminolevulinate in Daylight Therapy for Actinic Keratosis Patients

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Metformin Embonate
  • Sponsor:Fundacion Instituto De Investigacion Sanitaria Aragon

Diabetic foot

Not yet recruiting

Study on the Safety and Effects of Udonitrectag for Treating Diabetic Foot Ulcers in Patients

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:UDONITRECTAG
  • Sponsor:Mimetech S.r.l.

Diabetic foot+1

Not yet recruiting

Study on the Effectiveness of Autologous Bone Marrow-Derived Mononuclear Cells and Angioplasty in Diabetic Patients with Chronic Limb-Threatening Ischemia

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:AUTOLOGOUS BONE MARROW-DERIVED MONONUCLEAR CELLS
  • Sponsor:Institute For Clinical And Experimental Medicine

Systemic lupus erythematosus

Not yet recruiting

Study on the Effectiveness of Telitacicept for Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Telitacicept
  • Sponsor:Remegen Co. Ltd.

Henoch-Schonlein purpura

Not yet recruiting

Study of rituximab and glucocorticoids versus placebo and glucocorticoids in adults with newly diagnosed or relapsing IgA vasculitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Hospital Foch

Skin cancer+1

Not yet recruiting

Study of DYP688 for Patients with Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dyp688
  • Sponsor:Novartis Pharma AG

Erythema multiforme

Not yet recruiting

Study on Severe Erythema Multiforme: Comparing Methylprednisolone Acetate and Lidocaine Hydrochloride Monohydrate with Placebo for Hospitalized Patients

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Assistance Publique Hopitaux De Paris

Neurofibromatosis

Not yet recruiting

Study on Trametinib for Patients with Neurofibromatosis Type 1 and Symptomatic Plexiform Neurofibromas

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Trametinib
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Novartis Pharma AG

Systemic scleroderma

Not yet recruiting

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Hand dermatitis

Not yet recruiting

Study Comparing Alitretinoin and Ciclosporin for Patients with Moderate to Very Severe Hand Eczema

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Alitretinoin
  • Sponsor:Universitair Medisch Centrum Groningen

Hidradenitis

Not yet recruiting

Study on the Use of Adipose-Derived Stem Cells for Treating Hidradenitis Suppurativa in Patients with Draining Fistulas

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Adipose-Derived Adult Mesenchymal Stem Cells Expanded
  • Sponsor:Red Andaluza De Diseno Y Traslacion De Terapias Avanzadas Fundacion Publica Andaluza Progreso Y Salud

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Pembrolizumab57 clinical trialsNivolumab33 clinical trialsSodium Chloride22 clinical trialsDeucravacitinib19 clinical trialsCemiplimab18 clinical trialsUpadacitinib17 clinical trialsIpilimumab15 clinical trialsRituximab13 clinical trialsCyclophosphamide12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.